Sickle Cell Society exploring gene therapy access to thalassemia patients

The Thalassemia and Sickle Cell Society (TSCS) is exploring ways to bring gene therapy access to patients in India. A delegation visited Thailand and other countries to study treatment protocols, infrastructure and collaboration opportunities with global experts

Hyderabad: The Thalassemia and Sickle Cell Society (TSCS) announced its efforts to bring gene therapy access to thalassemia patients across India.

As part of the initiative, a TSCS delegation traveled to Thailand and other countries recognized as the foremost destinations for gene therapy in thalassemia care, to evaluate treatment protocols, infrastructure, and potential collaboration opportunities.

---

The visit was in partnership with Dr. Sunil Bhat, senior bone marrow transplant (BMT) specialists, and TSCS team including president, Dr. Chandrakant Agarwal, Chief Medical Research Officer & Secretary, Dr Suman Jain, vice-president, Dr Naresh Rathi, senior scientist Dr Nishant Mittal held discussions and tried to understand how gene therapy, an emerging and potentially transformative treatment option for thalassemia, could be made accessible to patients across the country.

TSCS plans work closely with experts and international partners to lay the groundwork for gene therapy in India.